AM-Pharma BV, of Bunnik, the Netherlands, was granted U.S. Patent No. 7,060,677, which claims the use of the hLF1-11 peptide and its derivatives to produce drugs against bacterial, fungal and viral infections.

Ariad Pharmaceuticals Inc., of Cambridge, Mass., was issued U.S. Patent No. 7,091,213, covering its mTOR inhibitors, which include its lead cancer product, AP23573, and the uses of those compounds in cancer and in preventing reblockage at sites of vascular injury following stent-assisted angioplasty.

Arrowhead Research Corp., of Pasadena, Calif., said U.S. Patent No. 7,091,192, titled "Linear Cyclodextrin Copolymers," was issued to the California Institute of Technology. That patent is licensed exclusively to Arrowhead's subsidiary, Insert Therapeutics Inc., and relates to a class of polymers for the delivery of therapeutics.

AVI BioPharma Inc., of Portland, Ore., received a notice for allowance for a patent, titled "Antisense Restenosis Composition and Method," covering the use of AVI-4126 in vascular injury. The company also was issued a notice of allowance for a patent, titled "Microbubble Compositions and Methods for Oligonucleotide Delivery," which covers the administration of drugs, including antisense drugs, via microbubbles to damaged vascular tissue.

Boston Life Sciences Inc., of Hopkinton, Mass., said U.S. Patent No. 7,081,238 was issued to Harvard, the General Hospital Corp. and Organix Inc. that covers methods of diagnosing and monitoring attention deficit hyperactivity disorder by assessing the level of dopamine transporter in at least one region of a patient's central nervous system.

Echelon Biosciences Inc., of Salt Lake City, received a patent covering non-radioactive, competitive phosphatidylinositol 3-kinase assays. PI3-K is a cellular enzyme that's often altered in diseases leading to abnormal cell growth in cancer and pathological cellular response in inflammation.

EntreMed Inc., of Rockville, Md., received U.S. Patent No. 7,087,592, covering composition of matter for its purified 2-methoxyestradiol product, Panzem NCD, which is in Phase I and Phase II trials for cancer.

Genaera Corp., of Plymouth Meeting, Pa., was issued U.S. Patent No. 7,056,698, titled "Nucleic Acids Encoding Interleukin-9 Receptor Variants," which relates to the diagnosis, treatment and methods of discovery of therapeutics for atopic asthma and related disorders based on variants of the IL-9 receptor.

Generex Biotechnology Corp., of Toronto, received a patent, titled "Method for Administering Insulin to the Buccal Region," which relates to an improved delivery system for the administration of large-molecule pharmaceuticals through the oral and nasal membranes. The company also received a patent, titled "Methods of Administering and Enhancing Absorption of Pharmaceutical Agents," covering claims for the delivery of macromolecules via the buccal cavity of the mouth.